Company / EPS (Diluted)
Sarepta Therapeutics EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.80
FY2025
5-year range
-$9.71 / -$5.15
FY2021-FY2025
Trend
+27.8%
vs FY2024
Sector context
#183 of 204
Health Care
What the data says
Among 204 Health Care companies, Sarepta Therapeutics is in the bottom 10% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-9.71 in FY2021 to $1.50 in FY2017.
Based on SEC 10-K filings.
-5.80 in FY2025.
Declined from $-5.15 to $-5.80 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 204This company -$5.80 Sector average -$0.89
▼
-554.5% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 27.8% year-over-year.
- Ranks #183 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.80 | +27.8% |
| FY2024 | -$8.03 | -55.9% |
| FY2023 | -$5.15 | +27.6% |
| FY2022 | -$7.11 | +26.8% |
| FY2021 | -$9.71 | -77.8% |
| FY2020 | -$5.46 | -534.9% |
| FY2019 | -$0.86 | +84.3% |
| FY2018 | -$5.49 | -466.0% |
| FY2017 | $1.50 | +144.2% |
| FY2016 | -$3.39 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026